Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Dow Inc
DOW
|
+$123M |
| 2 |
Newmont
NEM
|
+$77.1M |
| 3 |
Corteva
CTVA
|
+$72.5M |
| 4 |
Amcor
AMCR
|
+$60.2M |
| 5 |
Alibaba
BABA
|
+$47.4M |
Top Sells
| 1 |
DuPont de Nemours
DD
|
+$101M |
| 2 |
Apple
AAPL
|
+$94.5M |
| 3 |
GG
Goldcorp Inc
GG
|
+$78.3M |
| 4 |
Microsoft
MSFT
|
+$77.6M |
| 5 |
Pfizer
PFE
|
+$53.9M |
Sector Composition
| 1 | Technology | 19.94% |
| 2 | Healthcare | 14.68% |
| 3 | Consumer Discretionary | 11.95% |
| 4 | Communication Services | 10.13% |
| 5 | Industrials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Gates Industrial
GTES
$6.67B
| $1.23M | ﹤0.01% |
107,900
+2,200
| +2% | +$25.1K |
|
2002
Amneal Pharmaceuticals
AMRX
$3.24B
| $1.23M | ﹤0.01% |
171,200
+3,600
| +2% | +$25.8K |
|
|
MODV
2003
DELISTED
ModivCare
MODV
| $1.23M | ﹤0.01% |
21,400
+400
| +2% | +$22.9K |
|
|
VRS
2004
DELISTED
Verso Corporation
VRS
| $1.23M | ﹤0.01% |
64,300
+1,300
| +2% | +$24.8K |
|
2005
Par Pacific Holdings
PARR
$1.72B
| $1.22M | ﹤0.01% |
59,359
+5,000
| +9% | +$103K |
|
2006
Mercer International
MERC
$208M
| $1.22M | ﹤0.01% |
78,772
+1,500
| +2% | +$23.2K |
|
|
NRE
2007
DELISTED
NorthStar Realty Europe Corp.
NRE
| $1.22M | ﹤0.01% |
74,158
-7,500
| -9% | -$123K |
|
2008
TG Therapeutics
TGTX
$5.11B
| $1.22M | ﹤0.01% |
140,500
+23,300
| +20% | +$201K |
|
2009
Allogene Therapeutics
ALLO
$255M
| $1.21M | ﹤0.01% |
+45,200
| New | +$1.21M |
|
2010
Kura Oncology
KURA
$724M
| $1.21M | ﹤0.01% |
61,400
+16,300
| +36% | +$321K |
|
2011
Verra Mobility
VRRM
$3.96B
| $1.21M | ﹤0.01% |
+92,100
| New | +$1.21M |
|
2012
Bloom Energy
BE
$15.7B
| $1.2M | ﹤0.01% |
+98,100
| New | +$1.2M |
|
2013
ATN International
ATNI
$240M
| $1.2M | ﹤0.01% |
20,800
+500
| +2% | +$28.9K |
|
2014
Ecovyst
ECVT
$1.09B
| $1.2M | ﹤0.01% |
75,800
+1,700
| +2% | +$26.9K |
|
2015
Phibro Animal Health
PAHC
$1.67B
| $1.2M | ﹤0.01% |
37,800
+900
| +2% | +$28.6K |
|
|
HNGR
2016
DELISTED
Hanger Inc.
HNGR
| $1.19M | ﹤0.01% |
+62,300
| New | +$1.19M |
|
2017
StoneX
SNEX
$5.17B
| $1.19M | ﹤0.01% |
67,725
+2,025
| +3% | +$35.6K |
|
|
GSKY
2018
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
| $1.19M | ﹤0.01% |
+96,600
| New | +$1.19M |
|
|
KBAL
2019
DELISTED
Kimball International
KBAL
| $1.18M | ﹤0.01% |
67,800
+1,000
| +1% | +$17.4K |
|
2020
Griffon
GFF
$3.73B
| $1.18M | ﹤0.01% |
69,700
+11,400
| +20% | +$193K |
|
2021
Manitowoc
MTW
$366M
| $1.18M | ﹤0.01% |
66,250
+4,600
| +7% | +$81.9K |
|
2022
DXP Enterprises
DXPE
$1.87B
| $1.18M | ﹤0.01% |
31,000
+600
| +2% | +$22.7K |
|
2023
Banc of California
BANC
$2.64B
| $1.17M | ﹤0.01% |
84,000
+10,900
| +15% | +$152K |
|
|
UBA
2024
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $1.17M | ﹤0.01% |
55,736
+1,400
| +3% | +$29.4K |
|
2025
Cohu
COHU
$989M
| $1.17M | ﹤0.01% |
75,750
+1,600
| +2% | +$24.7K |
|